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Proanthocyanidins, compounds highly concentrated in dietary fruits, such as cranberries and grapes, demonstrate signiﬁcant
cancer prevention potential against many types of cancer. The objective of this study was to evaluate cranberry and grape seed
extracts to quantitate and compare their anti-proliferative eﬀects on the most common type of oral cancer, oral squamous cell
carcinoma. Using two well-characterized oral squamous cell carcinoma cell lines, CAL27 and SCC25, assays were performed to
evaluate the eﬀects of cranberry and grape seed extract on phenotypic behaviors of these oral cancers. The proliferation of both
oral cancer cell lines was signiﬁcantly inhibited by the administration of cranberry and grape seed extracts, in a dose-dependent
manner. In addition, key regulators of apoptosis, caspase-2 and caspase-8, were concomitantly up-regulated by these treatments.
However, cranberry and grape seed extracts elicited diﬀerential eﬀects on cell adhesion, cell morphology, and cell cycle regulatory
pathways. This study represents one of the ﬁrst comparative investigations of cranberry and grape seed extracts and their anti-
proliferative eﬀects on oral cancers. Previous ﬁndings using puriﬁed proanthocyanidin from grape seed extract demonstrated
more prominent growth inhibition, as well as apoptosis-inducing, properties on CAL27 cells. These observations provide evidence
that cranberry and grape seed extracts not only inhibit oral cancer proliferation but also that the mechanism of this inhibition may
function by triggering key apoptotic regulators in these cell lines. This information will be of beneﬁt to researchers interested in
elucidatingwhichdietarycomponentsarecentraltomechanismsinvolvedinthemediationoforalcarcinogenesisandprogression.
1.Introduction
A growing interest has developed in the ﬁelds of nutrition,
dietetics and complementary medicine to identify dietary
components and botanical or nutritional supplements for
theirspeciﬁcchemopreventiveandchemotherapeuticpoten-
tials [1, 2]. The consumption of speciﬁc foods or nutrients,
such as fruits and vegetables, may be both a convenient
and cost-eﬀective method for the administration of bene-
ﬁcial and protective bioactive compounds. However, more
detailed information is needed to identify the active compo-
nents in these foods to evaluate dose-response relationships
and toxicity, and to adjust for potential confounders in order
to make these recommendations.
Multivariate meta-regression analysis from previous
nutrition studies has revealed that the reduction in oral
cancer risk by fruit consumption was signiﬁcantly inﬂuenced
by the type of fruit consumed, with other factors less
signiﬁcant [3]. This larger protective eﬀect from developing
oral cancer was most closely associated with citrus fruits
and berries, rather than overall fruit consumption, even after
adjusting for sex, age, tobacco or alcohol use. Based upon
these studies and other epidemiologic and laboratory-based
projects, a large number of anti-cancer agents derived from
fruits and vegetables, particularly citrus fruits and berries,
have been identiﬁed. These include ﬂavonoids and polyphe-
nolics, carotenoids, dithioltiones, glucosinolates, indoles,
isothiocyanates, protease inhibitors, plant sterols, allium
compounds, limonenes, selenium, vitamin C, vitamin E and
dietary ﬁber [1, 4].
An interest has developed in one class of these com-
pounds which exhibit chemopreventive and chemothera-
peutic potential in many stages of oral carcinogenesis, the
proanthocyanidins, which are highly concentrated in certain
dietary fruits, nuts and berries. Proanthocyanidins (PACs)
are polyphenolic compounds derived from common dietary2 Evidence-Based Complementary and Alternative Medicine
f o o d ss u c ha sg r a p e s ,c r a n b e r r i e sa n da l m o n d s ,a sw e l la s
chocolate and cacao beans [5–9]. Recent evidence suggests
that PACs exhibit cytotoxicity against some cancers, includ-
ing colon, breast and prostate cancers [10–15]. Moreover,
studies involving raspberry-, grape- and grape seed-derived
PACs have recently demonstrated selective inhibition of
oral cancer phenotypes, particularly in oral squamous cell
carcinomas (OSCC) [16, 17].
To more closely examine the potential relationship
between PACs and the inhibition of oral cancer phenotypes,
the speciﬁc eﬀects of grape-seed extracts (GSE)-derived
PAC administration on the in vitro proliferation of the
most common of oral cancers, OSCC were assessed [18].
The results demonstrated that the administration of GSE-
derived PACs was suﬃcient to reduce the proliferation of an
OSCC cell line, CAL27, in a dose-dependent manner [18].
Moreover, the eﬀects of GSE-PACs were more selective, and
intenselyspeciﬁc,fortheOSCCcellline comparedwithnon-
cancerous controls, suggesting a possible selective eﬀect that
may render oral cancers more susceptible to the apoptosis-
inducing and proliferation-inhibiting eﬀects of PACs.
Although the aforementioned studies have provided cru-
cial information towards our understanding of oral cancer
growth inhibition in vitro, thus far none have compared
various PAC-containing extracts for their ability to inhibit
oral cancer growth. Studies which demonstrated the inhi-
bition of oral cancer proliferation in vitro using ﬂavonoid-
and proanthocyanidin-rich extracts from grape seed- [16],
raspberry- [17] and cranberry-extracts [9] suggest that PACs
derived from many dietary sources may function in oral
cancer chemoprevention. No published study to date, how-
ever, has incorporated multiple PACs to provide comparative
evaluation of these anti-proliferative and growth-inhibitory
properties in multiple oral cancer cell lines.
Assessing dietary and nutrition information to provide
speciﬁc recommendations for patients with increased risk
for developing oral cancers is extremely challenging, partly
due to the diﬃculties surrounding the confounding eﬀects
of other behaviors and risks, but also due to the dearth
of information regarding the speciﬁc eﬀects of particular
dietary components on oral cancer phenotypes. Therefore,
the aim of this study was to evaluate two PAC sources,
cranberry extract (CE) and GSE, to investigate and compare
their anti-proliferative and growth-inhibitory eﬀects. More
importantly, these results can be contextualized with our
previous studies of puriﬁed GSE-derived PACs, to more
accurately assess the potential value for further studies of
PAC-induced inhibition of oral cancers and for speciﬁc
recommendations for testing of PACs for future animal and
human clinical trials.
2. Methods
2.1.Materials. Grapeseedextract(GSE)(Lot#0549BG1980)
from US wine grapes (Vitus vinifera)a n dc r a n b e r r y( Vac-
cinium macrocarpon) extract (CE) (Lot #1367CG1936) were
obtained from GNC Prevention Nutrition (Pittsburgh,
PA). CE contains oligomeric and polymeric polyphenols,
including PACs [9], while GSE has been demonstrated
to contain 95% PACs, with 80–90% oligomeric PACs,
including dimers, trimers, tetramers, and a small amount of
monomeric ﬂavonoids [19, 20].
2.2. Cell Culture. The human OSCC cell lines used in this
study, CAL27 and SCC25, were obtained from American
Type Culture Collection (ATCC: Manassas, VA). CAL27 cells
were maintained in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) with 4mM l-glutamine, adjusted to contain
3.7g/l sodium bicarbonate and 4.5g/l glucose from Hyclone
(Logan, UT). SCC25 cells were maintained in a 1:1 mix-
ture of DMEM and Ham’s F12 medium with 2.5mM l-
glutamine, modiﬁed to contain 15mM HEPES, 0.5mM
sodium pyruvate, and 1.2g/l sodium bicarbonate (ATCC),
supplemented with 400ng/ml hydrocortisone from Sigma-
Aldrich (St Louis, MO). Media for all cell lines was supple-
mented with 10% fetal bovine serum (FBS) and 1% Peni-
cillin (10000units/ml)–Streptomycin (10000μg/ml) solu-
tion (HyClone). Cell cultures were maintained in 75cm2 BD
Falcon tissue-culture treated ﬂasks (Bedford, MA) at 37◦C
and 5% CO2 in humidiﬁed chambers.
2.3. Proliferation. Proliferation assays of CAL27 and SCC25
cells were performed in the appropriate complete media,
with and without the addition of GSE and CE. The total
concentrations of GSE and CE used were between 10 and
80μg/ml, added to the complete media prior to the start of
each experimental assay and cell plating. Four independent
replications of each experiment (CE, GSE) for each cell line
(CAL27, SCC25) were performed (n = 288), each consisting
of eight wells per experimental concentration (0, 10, 20, 30,
40, 50, 60, 70 and 80 μg/ml, n = 72 wells/plate). Cells were
plated in Corning Costar high-throughput, 96-well assay
plates (Corning, NY) at a concentration of 1.2 × 104 cells per
well, which roughly approximates 30–40% conﬂuence per
wellattheonsetofeachassay;proliferationwassubsequently
measured over 3 days. Cultured cells were ﬁxed after 24 h
(day 1), 48h (day 2) and 72h (day 3) using 50μl of 10%
buﬀered formalin, and were stained with crystal violet 1%
aqueous solution (Fisher Scientiﬁc: Fair Lawn, NJ). The
relative absorbance was measured at 630nm using a Bio-
Tek ELx808 microplate reader (Winooski, VT). Data were
analyzed and graphed using Microsoft Excel (Redmond,
WA) and SPSS (Chicago, IL). Four separate, independent
replications of each experimental condition were performed
(CE, GSE) for each cell line (CAL27, SCC25) (n = 288).
2.4. Adhesion. Cell adhesion assays of CAL27 and SCC25
cells were performed, as previously described [21, 22], in
uncoated Corning Costar 96-well assay plates at a concen-
tration of 1.2 × 105 cells per well (100μlo f1 . 2× 106 cells/ml
solution). Cells were suspended in the appropriate media, as
described above in cell culture methods; with no additives,
withandwithouttheadditionofGSEandCEattheindicated
concentrations. Cells were allowed to attach for 30 min at
37◦C with one modiﬁcation to the standard adhesion assay
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step, in which non-adherent cells are generally removed
by suspending the plate upside-down in a rotating tank
of PBS, as previously described [18, 23]. Following the
incubation period, cells were ﬁxed using 50μl of 10%
buﬀered formalin and were subsequently stained with crystal
violet 1% aqueous solution. The relative absorbance was
then measured at 630nm using a Bio-Tek ELx808 microplate
reader. Data were analyzed and graphed using Microsoft
Excel. Three separate, independent replications of each
experimental condition were performed (CE, GSE) for each
cell line (CAL27, SCC25) (n = 216).
2.5. Statistics. The diﬀerences between treatments were
measured using a t distribution, α = .05. All samples were
analyzedusingtwo-tailedt-testsasdeparturefromnormality
c a nm a k em o r eo fad i ﬀerence in a one-tailed than in a two-
tailed t-test. As long as the sample size is even moderate
(>20)foreachgroup,quiteseveredeparturesfromnormality
make little practical diﬀerence in the conclusions reached
from these analyses [24]. However, analyses involving multi-
ple two sample t-tests may have a higher probability of Type
I error, leading to false rejection of the null hypothesis, H0
[24]. To conﬁrm the eﬀects observed from these experiments
and minimize the possibility of Type I error, further analysis
of the data was facilitated with ANOVA using SPSS (Chicago,
IL) to more accurately assess the relationship and statistical
signiﬁcance among and between groups.
2.6. Microscopy of Cell Morphology and Viability. Cells were
visualized with a Zeiss Axiovert 40 inverted microscope
(Gottingen, Germany), and images were captured at 200 ×
magniﬁcation with a Canon PowerShot G6 digital camera
(Tokyo, Japan). Digital images were subsequently processed
using Adobe Photoshop (San Jose, CA) Image Analysis
tools. In brief, several wells of CAL27 and SCC25 cells were
photographed from the adhesion assays and also from each
time point of the proliferation assays (day 1, day 2, day 3)
at each concentration of the treatment conditions (CE, GSE;
0–80μg/ml) to visualize any eﬀects on cell morphology, pre-
ﬁxation. In addition, several wells of cells were also ﬁxed at
these time points using 50μl of 10% buﬀered formalin and
subsequently stained using crystal violet 1% aqueous solu-
tion to quantitatively document cell morphology, percent
of cell spreading and conﬂuence. Additionally, at each time
point, several wells were stained using Trypan Blue, and live
cells were enumerated to determine viability, as previously
described [25, 26].
2.7. RT-PCR. RNA was isolated from 1.5 × 107 cells
of CAL27 and SCC25 cells at 24 h after CE or GSE
administration using ABgene Total RNA Isolation Reagent
(Epsom, Surrey, UK) and the procedure recommended by
themanufacturer.RT-PCRwasperformedontotalRNAwith
the ABgene Reverse-iT One-Step RT-PCR Kit (ReadyMix
Version) and a Mastercycler gradient thermocycler (Eppen-
dorf: Hamburg, Germany). The following primers for p53
[27], c-myc [28], ornithine decarboxylase (ODC) [29],
caspase-2 [30], caspase-3 [30], caspase-8 [31], bax [30]a n d
glyceraldehyde-3-phosphate dehydrogenase GAPDH [29],
synthesized by SeqWright (Houston, TX), were used:
p53 forward primer, ACCAGGGCAGCTACGGTT-
TC;
p53 reverse primer, CCTGGGCATCCTTGAGTTCC;
c-myc forward primer, TCCAGCTTGTACCTG-
CAGGATCTGA;
c-myc reverse primer, CCTCCAGCAGAAGGTGAT-
CCAGACT;
ODC forward primer, AATCAACCCAGCGTTGGA-
CAA;
ODC reverse primer, ACATCACATAGTAGATCG-
TCG;
caspase-2 forward primer, TGGCATATAGGTTGC-
AGTCTCGG;
caspase-2 reverse primer, TGTTCTGTAGGCTTG-
GGCAGTTG;
caspase-3 forward primer, ACATGGAAGCGAATC-
AATGGACTC;
caspase-3 reverse primer, AAGGACTCAAATTCT-
GTTGCCACC;
caspase-8 forward primer, GATATTGGGGAACAA-
CTGGAC;
caspase-8 reverse primer, CATGTCATCATCCAG-
TTTGCA;
bax forward primer, GGTTTCATCCAGGATCGA-
GACGG;
bax reverse primer, ACAAAGATGGTCACGGTC-
TGCC;
GAPDH forward primer, ATCTTCCAGGAGCGA-
GATCC;
GAPDH reverse primer, ACCACTGACACGTTG-
GCAGT.
One microgram of template (total) RNA was used
for each reaction. The reverse transcription step ran for
30min at 47◦C, followed by denaturation for 2min at
94◦C. Thirty-ﬁve ampliﬁcation cycles were run, consisting
of 20s denaturation at 94◦C, 30s of annealing at 58◦C,
and 6.5min of extension at 72◦C. Final extension was run
for 5min at 72◦C. Reaction products were separated by gel
electrophoresisusingReliant4%NuSieve 3:1PlusAgarose
gels (Lonza: Rockland, ME). Bands were visualized by UV
illumination of ethidium-bromide-stained gels and captured
using a Kodak Gel Logic 100 Imaging System and 1D
Image Analysis Software (Eastman Kodak: Rochester, NY).
Quantitation of RT-PCR band densitometry was performing
using Adobe (San Jose, CA) Photoshop imaging software,
Image Analysis tools.4 Evidence-Based Complementary and Alternative Medicine
3. Results
3.1. Proliferation
3.1.1.CAL27. CAL27cellsweregrownin96-wellassayplates
and their proliferation was measured over 3 days in four
separate, independent experimental trials to determine if
the administration of either CE or GSE was suﬃcient to
inhibitcellularproliferation.Theresultsoftheseexperiments
demonstratedthatCAL27cellularproliferationwasinhibited
in a dose-dependent manner by both CE and GSE, although
their eﬀects were distinct from one another. The maximal
growthinhibitoryconcentrations(GIMAX)ofCEandGSEon
CAL27 cells also exhibited distinctive patterns.
All concentrations of CE (10–80μg/ml) were suﬃcient to
inhibit proliferation of CAL27 cells (Figure 1), which exhib-
ited dose-dependent relationships (Figure 1(a)). To reduce
the proliferation-stimulating eﬀects of trypsin and plating
of cells into each experimental assay, previously observed
betweenday0andday1inmanyproliferationassays[18,32],
the relative change in proliferation was measured between
day 3 and day 1. This analysis revealed the GIMAX for CE on
CAL27 cells was 40μg/ml, inhibiting CAL27 growth by 34%
comparedwiththebaselinetreatmentcontrols(Figure 1(b));
conﬁrmation of the observations based directly from raw
data (Figure 1(a)).
Two tailed t-tests, performed to validate the reduction
in CAL27 proliferation at all CE concentrations, revealed
that all experimental concentrations resulted in statistically
signiﬁcant inhibition of proliferation (Figure 1(c))( n =
288, P < .01). Because these analyses involved multiple
two sample t-tests, with a higher probability of Type I
error, ANOVA was performed to more accurately assess the
relationship among groups. This analysis veriﬁed statistically
signiﬁcant diﬀerences between the experimental groups, but
not within the groups (Figure 1(c)), further corroborating
that statistically signiﬁcant diﬀerences in CAL27 prolifera-
tion were induced with CE administration.
The administration of GSE (10–20μg/ml), however,
did not inhibit proliferation of CAL27 cells, but rather
stimulated proliferation slightly—although this was not
statistically signiﬁcant (Figure 2). Higher concentrations of
GSE were, however, suﬃcient to inhibit proliferation of
CAL27cells,exhibitingastrongdose-dependentrelationship
at concentrations >30μg/ml (Figure 2(a)). The analysis of
relative change in proliferation between day 3 and day 1
revealed that the GIMAX for GSE on CAL27 cells was 70
μg/ml, inhibiting CAL27 proliferation by 38% compared
with the baseline treatment controls (Figure 2(b)).
Two tailed t-tests, performed to validate each reduction
in CAL27 proliferation at all GSE concentrations, revealed
that only experimental concentrations above 50μg/ml rep-
resented statistically signiﬁcant inhibitions in proliferation
(Figure 2(c)). ANOVA conﬁrmed statistically signiﬁcant dif-
ferences between the experimental groups, but not within
the groups (Figure 1(c)), providing further validation of the
statistical diﬀerences observed with GSE-induced inhibition
of CAL27 proliferation.
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Squares
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Square
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Between .456 8 .029 5.999 .000
Within 1.284 279 .005
Total 1.740 287
Two-tailed t-test (P value)
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CAL27 0.005893 0.000000
(c)
Figure 1: CE administration signiﬁcantly inhibited CAL27 pro-
liferation in vitro. CAL27 cells were plated in 96-well assay plates
with media containing 10% fetal bovine serum (FBS) in the
absence and presence of increasing CE concentrations (0–80μg/ml)
and were allowed to proliferate for 3 days. The addition of CE
induced dose-dependent inhibition of proliferation up to GIMAX
(–34%) at 40μg/ml (a) (n = 288, P < .01). Relative-fold increase
in proliferation conﬁrmed GIMAX at 40μg/ml (b), graphed as
the relative fold proliferation—measured by day 3 measurement
average minus day 1 measurement average (d3–d1). Two-tailed t-
test and one-way ANOVA conﬁrm statistical signiﬁcance of CE-
induced proliferation inhibition of CAL27 at all concentrations (c).
A colour version of this ﬁgure is available online as supplementary
data.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: GSE administration inhibited CAL27 proliferation in
vitro. CAL27 cells were plated in 96-well assay plates with media
containing 10% fetal bovine serum (FBS) in the absence and
presence of increasing GSE concentrations (0–80μg/ml) and were
allowed to proliferate for 3 days. The addition of GSE at low con-
centration (10–20μg/ml) stimulated proliferation of CAL27 cells,
while increasing concentrations elicited dose-dependent inhibition
uptoGIMAX (–38%)at70μg/ml(a)(n =288,P < .01).Relative-fold
increase in proliferation conﬁrmed GIMAX at 70μg/ml (b), graphed
as the relative fold proliferation—measured by day 3 measurement
average minus day 1 measurement average (d3–d1). Two-tailed t-
test and one-way ANOVA conﬁrm statistical signiﬁcance of GSE
proliferation inhibition of CAL27 at concentrations >50μg/ml (c).
A colour version of this ﬁgure is available online as supplementary
data.
3.1.2. SCC25. SCC25 cells were also seeded in 96-well assay
plates and their proliferation was measured over 3 days in
four separate, independent experimental trials to determine
if the administration of CE or GSE was suﬃcient to
inhibitcellularproliferation.Theresultsoftheseexperiments
demonstratedthatSCC25cellularproliferationwasinhibited
in a dose-dependent manner by both CE and GSE, although
the inhibitory eﬀects of these extracts were also distinct
from one another. Unlike CAL27, however, the GIMAX
concentrations for both CE and GSE on the SCC25 cell line
were identical.
Low concentrations of CE (10–20μg/ml) did not inhibit
proliferation of SCC25 cells, but rather stimulated prolifer-
ation slightly more than control cells without treatment—
although this was not statistically signiﬁcant (Figure 3).
Higher concentrations of CE were, however, suﬃcient to
inhibit proliferation of SCC25 cells, exhibiting a gradu-
ated, increasing dose-dependent relationship for inhibition
(Figure 3(a)). The analysis of relative change in proliferation
between day 3 and day 1 revealed that the GIMAX for
CE on SCC25 cells was 70μg/ml, demonstrating reduced
proliferation of SCC25 by 36.3% compared with the baseline
treatment controls (Figure 3(b)).
Two tailed t-tests, performed to validate each reduction
in SCC25 proliferation at all CE concentrations, revealed
that only experimental concentrations above 50μg/ml rep-
resented statistically signiﬁcant inhibitions in proliferation
(Figure 3(c)). ANOVA was performed to more accurately
assess the relationship among groups. These results demon-
strated statistically signiﬁcant diﬀerences between the exper-
imental groups, but not within the groups (Figure 3(c)),
validating the statistical diﬀerences observed with CE-
induced inhibition of SCC25 proliferation above 50μg/ml.
All concentrations of GSE (10–80μg/ml) were suﬃcient
to inhibit proliferation of SCC25 cells (Figure 4), exhibiting
similar levels of proliferation inhibition that was dose-
dependent (Figure 4(a)). The relative change in proliferation
between day 3 and day 1 revealed that the GIMAX for GSE
on SCC25 cells was 70μg/ml, representing an inhibition of
SCC25 growth by 51.2% compared with baseline treatment
controls (Figure 4(b)).
Two tailed t-tests, performed to validate each reduction
in SCC25 proliferation at all GSE concentrations, revealed
that all experimental concentrations represented statistically
signiﬁcant inhibitions in proliferation (Figure 4(c)).ANOVA
conﬁrmed statistically signiﬁcant diﬀerences between all
of the experimental groups, but not within the groups
(Figure 4(c)), providing further validation of the statistical
diﬀerences observed with GSE-induced inhibition of SCC25
proliferation.
3.2. Adhesion. Based upon the results from the cellular
proliferation assays, in vitro cellular adhesion assays were
thenperformedusing30-minadhesionassaystodetermineif
any of the proliferation-inhibitory responses to CE or GSE in
these cell lines were correlated with quantiﬁable diﬀerences
inadhesion(Table 1).Theresultsoftheseassaysrevealedthat
CAL27 adhesion in vitro was altered by the administration6 Evidence-Based Complementary and Alternative Medicine
Table 1: CE- and GSE-induced eﬀects on CAL27 and SCC25 adhesion.
[0]μg/mL [10]μg/mL [20]μg/mL [30]μg/mL [40]μg/mL [50]μg/mL [60]μg/mL [70]μg/mL [80]μg/mL
CAL27:CE
AVE 0.169708 0.158833 0.140667 0.133083 0.136417 0.125792 0.132958 0.1185 0.126
STD 0.071633 0.046028 0.045456 0.03347 0.029181 0.031508 0.038637 0.024 0.027107
% change −0.064081 −0.171127 −0.215811 −0.19617 −0.258777 −0.216548 −0.301743 −0.25755
CAL27:GSE
AVE 0.189542 0.190417 0.163875 0.168625 0.186417 0.172917 0.1755 0.171708 0.177625
STD 0.064007 0.058357 0.039513 0.04395 0.068084 0.069489 0.060548 0.05999 0.052694
% change 0.004616 −0.135414 −0.110354 −0.016487 −0.087712 −0.074082 −0.094087 −0.062871
SCC25:CE
AVE 0.154542 0.146792 0.145958 0.150333 0.137042 0.124583 0.129625 0.141875 0.158875
STD 0.046158 0.029719 0.02906 0.044132 0.051973 0.028853 0.051599 0.046965 0.078825
% change −0.050148 −0.055541 −0.027231 −0.113238 −0.193853 −0.161229 −0.081963 0.02804
SCC25: GSE
AVE 0.16625 0.164625 0.16675 0.191708 0.176833 0.193208 0.198083 0.195333 0.227167
STD 0.052803 0.035287 0.034081 0.054233 0.049174 0.117639 0.071255 0.06047 0.081278
% change −0.009774 0.003008 0.153133 0.063659 0.162155 0.191479 0.174937 0.366416
Total n = 216; sample per assay, n = 24.
of either CE or GSE. More speciﬁcally, baseline CAL27
cellular adhesion was reduced in a dose-dependent manner
by increasing concentrations of CE, which were signiﬁcant at
all concentrations >50 μg/ml (n = 120, P < .01) (Figure 5);
with the greatest eﬀect observed at 70μg/ml (Figure 5(a)).
The administration of GSE induced an almost immediate
reductionin CAL27 adhesion, observedataconcentrationof
20μg/ml, while further increasing concentrations exhibited
diminishing inhibitory eﬀects on adhesion; none were
determined to be statistically signiﬁcant (n = 216, P > .05)
(Figure 5(a)).
The administration of CE and GSE, however, exhib-
ited dissimilar and less robust eﬀects compared with the
baseline levels of SCC25 cellular adhesion (Table 1). The
administration of increasing concentrations of CE reduced
SCC25 adhesion in a dose-dependent manner with maximal
reduction in adhesion observed at 50μg/ml (n = 24, P
< .01), the only concentration representing a statistically
signiﬁcant reduction, with all higher concentrations exhibit-
ing diminishing capacity to reduce SCC25 adhesion which
were not signiﬁcant (n = 192, P > .05) (Figure 5(b)). The
administration of increasing concentrations of GSE, how-
ever, induced measurable, though not signiﬁcant, increases
in SCC25 adhesion (n = 192, P > .05), except with the
maximal increase observed at 80μg/ml (n = 24, P < .01)
(Figure 5(b)).
3.3. Microscopy of Cell Morphology and Viability. GIMAX
concentrations of CE and GSE were suﬃcient to inhibit
proliferation of both cell lines, as well as inducing alterations
to cellular adhesion; therefore, microscopy was performed
to more accurately assess the qualitative eﬀects of CE
and GSE administration on CAL27 (Figure 6) and SCC25
cells (Figure 7). Compared with CAL27 controls without
treatment (Figures 6(a) and 6(d)), the administration of
CE at any concentration resulted in proliferation inhibition
and reduced cell number, an observation clearly visible in
all stained (Figure 6(b)) and unstained wells (Figure 6(e)).
The administration of GSE also inhibited CAL27 prolif-
eration at concentrations higher than 20μg/ml, and this
reductioninproliferationwasvisibleandapparentinstained
(Figure 6(c)) and unstained wells (Figure 6(f)). Although
cell proliferation was inhibited in both of the experimental
groups (CE, GSE), signiﬁcant alterations to cell morphology
and cell spreading were not observed with either treatment
or at any concentration.
The administration of CE and GSE on SCC25 cells
was suﬃcient to inhibit growth and proliferation, but was
also suﬃcient to induce alterations to cellular morphology
(Figure 7). In comparison to SCC25 control cells without
treatment (Figures 7(a) and 7(d)) the administration of CE
at concentrations >50μg/ml signiﬁcantly inhibited prolifer-
ation and induced phenotypic changes to cell morphology
(Figures 7(b) and 7(e)). All concentrations of GSE were
suﬃcient to signiﬁcantly inhibit SCC25 proliferation and
also induced visible phenotypic changes to cell morphology
(Figures 7(c) and 7(f)).
Because these experimental groups (CE, GSE) induced
diﬀerential responses and alterations to cell morphology
in the CAL27 and SCC25 cell lines over the course of 3
days, additional microscopy was performed to determine
if these eﬀects could be observed in experiments with a
shorter temporal component, such as the 30-min adhesion
assays (Figure 8). SCC25 control cells (Figure 8(a)) revealed
a marked increase in cell clustering and cell-cell adhe-
sion with the administration of CE (Figure 8(b)) or GSE
(Figure 8(c)). No notable diﬀerences in cell morphology or
arrangement were noted, however, between CAL27 control
cells (Figure 8(d)) and CE-treated (Figure 8(e)) or GSE-
treated (Figure 8(f)) cells.Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: CE administration inhibited SCC25 proliferation in vitro.
SCC25 cells were plated in 96-well assay plates with media con-
taining 10% fetal bovine serum (FBS) in the absence and presence
of increasing CE concentrations (0–80 μg/ml) and were allowed to
proliferate for 3 days. The addition of CE at low concentration (10–
20 μg/ml) stimulated proliferation of SCC25 cells, while increasing
concentrations elicited dose-dependent inhibition up to GIMAX (–
36%) at 70 μg/ml (a) (n = 288, P < .01). Relative-fold increase
in proliferation conﬁrmed GIMAX at 70μg/ml (b), graphed as
the relative fold proliferation—measured by day 3 measurement
average minus day 1 measurement average (d3–d1). Two-tailed t-
test and one-way ANOVA conﬁrm statistical signiﬁcance of CE
proliferation inhibition of SCC25 at concentrations >50μg/ml (c).
A colour version of this ﬁgure is available online as supplementary
data.
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Figure 4: GSE administration signiﬁcantly inhibited SCC25 pro-
liferation in vitro. SCC25 cells were plated in 96-well assay plates
withmediacontaining10%fetalbovineserum(FBS)intheabsence
and presence of increasing GSE concentrations (0–80μg/ml) and
were allowed to proliferate for 3 days. The addition of GSE induced
signiﬁcant, dose-dependent inhibition of proliferation up to GIMAX
(–51%) at 70μg/ml (a) (n = 288, P < .01). Relative-fold increase
in proliferation conﬁrmed GIMAX at 70μg/ml (b), graphed as
the relative fold proliferation—measured by day 3 measurement
average minus day 1 measurement average (d3–d1). Two-tailed t-
test and one-way ANOVA conﬁrm statistical signiﬁcance of GSE-
induced proliferation inhibition of SCC25 at all concentrations (c).
A colour version of this ﬁgure is available online as supplementary
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Figure 5:CEinhibitedadhesionofOSCCcelllinesinvitrowhileGSEhadvariableeﬀects.TheadditionofCEreducedCAL27(a)andSCC25
(b) adhesion signiﬁcantly at 70 (–30%, n = 216, P < .01) and 50μg/ml (–19%, n = 216, P = .01), respectively. The addition of GSE, however,
reduced CAL27 adhesion (not signiﬁcant, n = 216, P = .10) while signiﬁcantly increasing SCC25 adhesion (+36.6%, n = 216, P < .01). CE,
GSE P-values and relative change percentages are presented in Table 1. A colour version of this ﬁgure is available online as supplementary
data.
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Figure 6: Eﬀects of CE and GSE on CAL27 cell morphology
in vitro. CAL27 cell morphology from proliferation assays, ﬁxed
with formalin and stained with crystal violet (a–c) or pre-ﬁxation
(d–f) demonstrate reduced proliferation and lower cell numbers
under CE (b, e) or GSE (c, f) treatment compared with untreated
controls (a, d). A colour version of this ﬁgure is available online as
supplementary data.
Our previous work with CAL27 and puriﬁed GSE-
derived PAC revealed that GIMAX concentrations (50μg/ml)
were suﬃcient not only to inhibit proliferation, but also to
induce phenotypic changes in cell viability and morphology
[18]. A comparison of the previous observations with this
current study reveals notable diﬀerences in cell viability
and cell spreading among treatment groups (Figure 9). For
example, although CE and GSE reduced CAL27 proliferation
(–34%, –38%, resp.), this eﬀect was comparatively smaller
than the eﬀect of puriﬁed GSE-derived PAC (Figure 9(a)).
Moreover, although cell number and conﬂuence were
reduced signiﬁcantly by CE and GSE, cell viability and cell
spreading were not—in stark contrast to the observations
(a) (b) (c)
(d) (e) (f)
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Figure 7: Eﬀects of CE and GSE on SCC25 cell morphology
in vitro. SCC25 cell morphology from proliferation assays, ﬁxed
with formalin and stained with crystal violet ((a–c)) or pre-
ﬁxation ((d–f)) demonstrate reduced proliferation and lower cell
numbers under CE ((b, e)) or GSE ((c, f)) treatment compared
with untreated controls ((a, d)). Some cells displayed altered
morphology (am), which was not seen with either experimental
treatment of CAL27 cells. A colour version of this ﬁgure is available
online as supplementary data.
of CAL27 under the administration of puriﬁed GSE-derived
PAC (Figure 9(b)).
3.4. RT-PCR. To determine if the diﬀerential eﬀects of CE
and GSE administration on these cell lines was, in part, due
to diﬀerential expression of cell-cycle and apoptosis regula-
tory gene expression, RT-PCR was performed on total RNA
isolated from cultured CAL27 and SCC25 cells (Figure 10).
Using oligonucleotide primers speciﬁc for mRNA of the
cell-cycle regulatory genes p53, c-myc and ODC,a sw e l la s
the apoptosis regulatory genes caspase-2, -3, -8 and bax,Evidence-Based Complementary and Alternative Medicine 9
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Figure 8: Eﬀects of CE and GSE on cell morphology in 30-
min adhesion assays. SCC25 ((a–c)) and CAL27 ((d–f)) cells
from adhesion assays were ﬁxed with formalin and stained with
crystal violet. Analysis of captured images revealed that SCC25
cell morphology (a) was signiﬁcantly altered and cell clustering
(cc) increased by the administration of CE (b) and GSE (c) at
GIMAX concentrations (50, 80μg/ml, resp.) where cells were present;
although signiﬁcant areas of each experimental well (CE, GSE) had
few, if any, adherent cells. CAL27 cells (d) exhibited no notable
diﬀerences in cell clustering or cell–cell adhesion under CE (e) or
GSE (f) administration. A colour version of this ﬁgure is available
online as supplementary data.
densitometric measurements of relative endpoint (RE) RT-
PCRbandintensityformRNAexpressionofthesegeneswere
compared to endogenous expression from untreated CAL27
(Figure 10(a)) and SCC25 (Figure 10(b)) cells.
These analyses revealed that administration of GSE on
CAL27 cells had no signiﬁcant eﬀect on the cell-cycle
gene products tested, while CE administration induced an
increase in expression of each: p53 (+44%), c-myc (+29%)
and ODC (+371%) without signiﬁcantly altering levels of
total RNA (Figure 10(a)). Conversely, the administration of
CE on SCC25 cells had no signiﬁcant eﬀect on cell-cycle
geneproducts,whileGSEadministration reducedexpression
of each: p53 (−51%), c-myc (−7%) and ODC (−21%)
without signiﬁcantly altering total RNA (Figure 10(b)). GSE
and CE treatment of CAL27 cells induced striking eﬀects to
mRNA levels of apoptosis-associated pathway modulators,
increasing expression of caspase-2 by +239% and +327%,
respectively and caspase-8 by +21 and +181%, respectively.
GSE and CE treatment of SCC25 cells also induced increased
expression of caspase-2 (+42%, +27%, resp.) and caspase-
8 (+2%, +27%, respectively), although these increases were
less robust. Interestingly, the administration of GSE was
suﬃcient to reduce expression of bax and caspase-3 mRNA
in both cell lines.
4. Discussion
Although the health beneﬁts and disease ﬁghting potential
of proper diet and good nutrition are well established in
the literature, more recent ﬁndings suggest that particular
dietary components, such as fruits and vegetables, are signif-
icant protective factors against oral cancer [3]. Moreover, the
overall level of protection and risk reduction associated with
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Figure 9: Proliferation inhibition of CAL27 comparison: PAC, CE
and GSE. Previous results of proliferation inhibition of CAL27 with
PAC were compared with the results of the current investigation.
GIMAX concentration of puriﬁed GSE-derived PAC (50μg/ml)
exhibited a slightly more robust inhibition of CAL27 growth than
CE or GSE (a). Comparison of current results with previous
observations using puriﬁed GSE-derived PAC demonstrated that
although all treatments (PAC, CE, GSE) reduced cell number and
inhibited proliferation, to varying degrees, puriﬁed GSE-derived
PAC most decreased cell viability (–72%) and cell spreading (–
80%) (b). A colour version of this ﬁgure is available online as
supplementary data.
consumption of speciﬁc fruit and vegetables has suggested
this protection may be more strongly correlated with par-
ticular citrus fruits and berries [16, 17]. These observations
have provided strong evidence for the continued study of
one group of compounds highly concentrated in these foods
[5–9], proanthocyanidins (PACs), which demonstrated sig-
niﬁcant chemoprevention and chemotherapeutic potential
againstawiderangeofcancersandmorerecentlyagainstoral
cancers [16–18].
Although other studies have demonstrated that partic-
ular PAC-containing fractions of grape-seed, cranberry or
raspberry extracts may exhibit cytotoxic or anti-proliferative
eﬀects, none have yet provided direct comparisons of the
eﬀectsofPACsfromdiﬀeringsourcesinoraltumorcelllines.
The overall goal of this study, therefore, was to evaluate two10 Evidence-Based Complementary and Alternative Medicine
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Figure 10: Total RNA and mRNA analysis. RT-PCR was performed on total RNA extracted from CAL27 (a) and SCC25 (b) cells at 24 h
after CE or GSE administration; no signiﬁcant changes were detected at 4 h (data not shown). Relative endpoint (RE) RT-PCR revealed that
CE and GSE treatment increased expression of apoptosis-related mRNA (caspase-2, caspase-8) in both cell lines, which is ﬁrst detectable
at 24h. CE signiﬁcantly enhanced CAL27 expression of cell-cycle genes (p53, c-myc, ODC), while GSE reduced SCC25 expression of these
same targets at this time point.
commercially available PAC sources, cranberry extract (CE)
and grape seed extract (GSE), to investigate and compare
theiranti-proliferativeandgrowth-inhibitoryeﬀectsonwell-
characterized oral cancer cell lines in vitro. The initial
working hypothesis was that both CE and GSE would be
suﬃcient to mediate the proliferative phenotype of oral
cancers, allowing for quantitative diﬀerences to be identiﬁed.
These analyses did conﬁrm the inhibition of cellular
proliferation observed in previous studies [16–18]. Notably,
CE and GSE treatments signiﬁcantly reduced cell growth and
proliferation of both oral tumor cell lines between 30 and
50%,comparedwiththenon-treatedcontrols.However,cell-
line-speciﬁc eﬀects are known to occur and natural com-
pounds and extracts, such as CE and GSE used in this study,
may produce their eﬀects either directly or indirectly [33]
via multiple pathways, including apoptosis-related pathways,
such as caspase-2, caspase-3, and -8 [13, 34–36]. A further
analysis of these speciﬁc molecular pathways in CAL27 and
SCC25 cells, under CE and GSE administration, revealed a
common, dramatic up-regulation of mRNA expression in
both the apoptosis initiator, caspase-2, and the apoptosis
eﬀector, caspase-8, from CAL27 and SCC25 cell lines within
24h; unambiguous indicators that these speciﬁc apoptosis-
inducing factors were directly aﬀected by these treatments
and thus may be involved, to some degree, in the observed
phenotypic changes.
Althoughsomephenotypicchanges,suchasproliferation
inhibition, were comparable, other phenotypic changes and
molecular pathways altered by CE and GSE were strikingly
dissimilar. CE reduced cellular adhesion in both cell lines,
while GSE increased SCC25 adhesion and concomitantly
increased cell-cell clustering, but produced no signiﬁcant
eﬀects in CAL27 cells. This diﬀers profoundly from our
previous study using puriﬁed GSE-derived PAC, which
produced no observable changes to either cell clustering
or cell-cell adhesion [18]. Analysis of molecular pathways,
commonly associated with oral tumor proliferation, revealed
further dissimilarities, most notably that GSE reduced
mRNA expression of p53, c-myc and ODC in SCC25 cells,
while CE enhanced their expression in the CAL27 cell line.
Because damaged genes and molecular pathways can vary
from tumor to tumor, genetic heterogeneity may oﬀer one
potential explanation of how these tumor cell lines might
behave diﬀerently under the same treatment—suggesting
this study mayrepresentacrucialﬁrststeptowardexplaining
which components may be involved with the CE- or GSE-
mediated phenotypic changes in oral cancer proliferation.
Both CE and GSE contain multiple substances, in
addition to their monomeric and oligomeric PACs, which
may have competing eﬀects on cellular phenotypes despite
their relatively low concentrations [1]. Carotenoids, dithi-
oltiones, glucosinolates, indoles, isothiocyanates, protease
inhibitors, plant sterols, allium compounds, limonenes,
selenium, vitamin C, vitamin E and dietary ﬁber, which may
be present in both CE and GSE, may be responsible for
modulating and mediating a variety of cellular phenotypes
and may be involved in the diﬀering phenotypic alterations
described in this study [1, 4]. In addition, these substancesEvidence-Based Complementary and Alternative Medicine 11
are likely to inﬂuence multiple pathways in addition to
those that are directly or indirectly modulated by PACs
[34]. For example, although PACs, GSE and other ﬂavonoid
extracts are known to activate apoptosis-related pathways
[13, 35–37], while inhibiting aromatase [38] and ornithine
decarboxylase (ODC) in epithelial tumors [9, 39, 40], these
additionaltracesubstancesfoundinCEandGSEmayexhibit
diﬀering, or even competing, eﬀects which must also be
considered potential confounders.
Because botanical extracts may have additive or synergis-
tic eﬀects, as well as competing or confounding eﬀects [33],
comparisons of these eﬀects on well-characterized tumor
cell lines provide a framework and model for the discussion
andanalysisofpotentialbiologicalmechanismsthatproduce
clinical eﬀects [41, 42]. Such studies have helped to identify
chemopreventive and chemotherapeutic agents that provide
selective eﬀects against cancerous cells without untoward
eﬀects to normal cells and tissues [43]. The growing
evidence that CE and GSE may be eﬀective adjuvants and
complementary treatments for breast, colon and prostate
cancers, combined with these results, suggests the possibility
that CE and GSE may provide selective inhibition of oral
cancers, at least in vitro. Because evidence now suggests that
CE, GSE or PACs, administered as dietary supplements, are
non-toxic and bioavailable in both serum and tissues at
μg/ml concentrations, they may be promising candidates for
further exploration as adjuvant or complementary therapies
for patients with, or at risk of developing, oral cancers
[44, 45].
Supplementary Data
Supplementary data are available at eCAM Online.
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